KR20240154691A - 항-말라리아 백신으로서의 바이오융합 단백질 - Google Patents

항-말라리아 백신으로서의 바이오융합 단백질 Download PDF

Info

Publication number
KR20240154691A
KR20240154691A KR1020247034516A KR20247034516A KR20240154691A KR 20240154691 A KR20240154691 A KR 20240154691A KR 1020247034516 A KR1020247034516 A KR 1020247034516A KR 20247034516 A KR20247034516 A KR 20247034516A KR 20240154691 A KR20240154691 A KR 20240154691A
Authority
KR
South Korea
Prior art keywords
glu
val
lys
ile
asn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247034516A
Other languages
English (en)
Korean (ko)
Inventor
피에르 드륄르
Original Assignee
백4올 피티이 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 백4올 피티이 리미티드 filed Critical 백4올 피티이 리미티드
Publication of KR20240154691A publication Critical patent/KR20240154691A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445Plasmodium
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/002Protozoa antigens
    • A61K39/015Hemosporidia antigens, e.g. Plasmodium antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
KR1020247034516A 2016-07-21 2017-07-21 항-말라리아 백신으로서의 바이오융합 단백질 Pending KR20240154691A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP16180544.5 2016-07-21
EP16180544 2016-07-21
PCT/SG2017/050369 WO2018017020A1 (en) 2016-07-21 2017-07-21 Biofusion proteins as anti-malaria vaccines
KR1020197005103A KR20190090775A (ko) 2016-07-21 2017-07-21 항-말라리아 백신으로서의 바이오융합 단백질

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197005103A Division KR20190090775A (ko) 2016-07-21 2017-07-21 항-말라리아 백신으로서의 바이오융합 단백질

Publications (1)

Publication Number Publication Date
KR20240154691A true KR20240154691A (ko) 2024-10-25

Family

ID=56550732

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020247034516A Pending KR20240154691A (ko) 2016-07-21 2017-07-21 항-말라리아 백신으로서의 바이오융합 단백질
KR1020197005103A Ceased KR20190090775A (ko) 2016-07-21 2017-07-21 항-말라리아 백신으로서의 바이오융합 단백질

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197005103A Ceased KR20190090775A (ko) 2016-07-21 2017-07-21 항-말라리아 백신으로서의 바이오융합 단백질

Country Status (10)

Country Link
US (2) US20210038706A1 (https=)
EP (2) EP3487526B1 (https=)
JP (2) JP2019526274A (https=)
KR (2) KR20240154691A (https=)
CN (1) CN109963586B (https=)
AU (1) AU2017300965B2 (https=)
BR (1) BR112019001115A2 (https=)
CA (1) CA3031399A1 (https=)
TW (1) TWI780058B (https=)
WO (1) WO2018017020A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020017962A1 (en) * 2018-07-16 2020-01-23 Dcprime B.V. A combination product for use in tumor vaccination.
WO2020033398A1 (en) * 2018-08-06 2020-02-13 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating atii cell-dependent lung diseases
ES3016535T3 (en) * 2018-11-23 2025-05-09 Strike Pharma Ab Bi-specific conjugates
CA3133410A1 (en) 2019-04-25 2020-10-29 Dcprime B.V. Methods of tumor vaccination
NL2023863B1 (en) * 2019-09-20 2021-05-25 Univ Griffith Protein particles and uses thereof
CN111135290A (zh) * 2020-01-16 2020-05-12 定山石生物科技(北京)有限公司 一种用于激活人体免疫细胞的多肽试剂
CN115916963A (zh) 2020-03-27 2023-04-04 门德斯有限公司 白血病来源的经修饰细胞用于增强过继性细胞治疗的效力的离体用途
EP4171617A1 (en) 2020-06-30 2023-05-03 Mendus B.V. Use of leukemia-derived cells in ovarian cancer vaccines
JP2024506249A (ja) 2021-01-22 2024-02-13 メンドゥス・ベスローテン・フェンノートシャップ 腫瘍ワクチン接種の方法
BE1029148B1 (fr) * 2021-02-26 2022-09-26 Curavac Europe Vaccin pour un traitement therapeutique ou prophylactique de la myastenie grave
CN118207228B (zh) * 2024-03-21 2025-03-14 中国科学院上海免疫与感染研究所 一种防治结合的多时期双靶点串联疟疾mRNA疫苗

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1156825A2 (en) * 1999-02-25 2001-11-28 SMITHKLINE BEECHAM BIOLOGICALS s.a. Immunogens comprising a peptide and a carrier derived from h.influenzae protein d
DK200201741A (da) * 2002-11-12 2003-09-16 Statens Seruminstitut Vaccine comprising chimeric malaria proteins derived from Plasmodium falciparum
US20050112133A1 (en) * 2003-10-24 2005-05-26 Pierre Druilhe GLURP-MSP3 fusion protein, immunogenic compositions and malarial vaccines containing it
JP4696079B2 (ja) * 2003-12-17 2011-06-08 ヤンセン アルツハイマー イミュノセラピー Aβ免疫原性ペプチド担体結合物およびそれの製造方法
KR101895768B1 (ko) * 2011-06-01 2018-09-07 시아먼 유니버시티 디프테리아 독소 무독성 돌연변이 씨알엠197 또는 그의 단편을 포함하는 융합 단백질
WO2014136064A2 (en) * 2013-03-08 2014-09-12 Pfizer Inc. Immunogenic fusion polypeptides

Also Published As

Publication number Publication date
JP2022116169A (ja) 2022-08-09
US20220409712A1 (en) 2022-12-29
KR20190090775A (ko) 2019-08-02
CA3031399A1 (en) 2018-01-25
TWI780058B (zh) 2022-10-11
US20210038706A1 (en) 2021-02-11
JP7579298B2 (ja) 2024-11-07
EP3487526B1 (en) 2022-07-06
AU2017300965A1 (en) 2019-02-07
TW201803907A (zh) 2018-02-01
WO2018017020A1 (en) 2018-01-25
BR112019001115A2 (pt) 2019-06-25
EP4147715A1 (en) 2023-03-15
CN109963586A (zh) 2019-07-02
JP2019526274A (ja) 2019-09-19
AU2017300965B2 (en) 2024-09-12
CN109963586B (zh) 2023-11-03
EP3487526A1 (en) 2019-05-29

Similar Documents

Publication Publication Date Title
JP7579298B2 (ja) 抗マラリアワクチンとしてのバイオ融合タンパク質
Bargieri et al. New malaria vaccine candidates based on the Plasmodium vivax Merozoite Surface Protein-1 and the TLR-5 agonist Salmonella Typhimurium FliC flagellin
Drew et al. Humoral immune responses to DNA vaccines expressing secreted, membrane bound and non-secreted forms of the: Taenia ovis 45W antigen
WO1997030158A9 (fr) Proteine recombinante contenant un fragment c-terminal de msp-1 de plasmodium
WO2009082440A2 (en) Compositions of toll-like receptor agonists and malaria antigens and methods of use
US20070003562A1 (en) GLURP-MSP3 fusion protein, immunogenic compositions and malarial vaccines containing it
Cheong et al. Immunogenicity of bacterial-expressed recombinant Plasmodium knowlesi merozoite surface protein-142 (MSP-142)
Bargieri et al. Immunogenic properties of a recombinant fusion protein containing the C-terminal 19 kDa of Plasmodium falciparum merozoite surface protein-1 and the innate immunity agonist FliC flagellin of Salmonella typhimurium
Abdian et al. Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against Leishmania major infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis
CN100421730C (zh) 免疫原性组合物
JP2000506381A (ja) マラリア原虫msp―1のc末端断片を含む組換えタンパク質
US12202865B2 (en) Multivalent malaria transmission-blocking vaccines
RU2341534C2 (ru) Иммуногенный гибридный полипептид против ожирения и вакцинная композиция на его основе
US20190374629A1 (en) Thermostable variants of p. falciparum pfrh5 which can be produced in bacterial cells
US20040063190A1 (en) Preparation and usage of plasmodium fusion antigen
Wang et al. Influence of glycosylphosphatidylinositol anchorage on the efficacy of DNA vaccines encoding Plasmodium yoelii merozoite surface protein 4/5
PL212249B1 (pl) Kompleks rybosomalnych bialek P z zarodzca malarii Plasmodium falciparum jako antygen patogenu malarii oraz sposób otrzymania tego antygenu i kaseta ekspresyjna do tego sposobu
WO2024249116A1 (en) A multi-stage vaccine antigen for malaria
WO2014188212A2 (en) Treatment and prevention of malaria
Fitri Down-selecting Circumsporozoite Protein-based Malaria Vaccine Formulations: A Comparison of Malaria Sporozoite Challenge Models
Ogun et al. The oligomerization domain of C4-binding protein acts as an adjuvant: a fusion protein of MSP119 with the murine C4bp domain protects mice against malaria.
HK1140229A (en) Vaccine composition comprising a mixture of a recombinant protein containing a c-terminal p19 fragment of the msp-1 protein from plasmodium falciparum and another recombinant p19 protein from a plasmodium homologous to p. falciparum

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20241016

Application number text: 1020197005103

Filing date: 20190220

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241115

Comment text: Request for Examination of Application